Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 10, 2010 - Issue 3
Submit an article Journal homepage
137
Views
5
CrossRef citations to date
0
Altmetric
Review

The economics of improved cancer survival rates: better outcomes, higher costs

Carin A Uyl-de Groot Institute for Medical Technology Assessment, Institute of Health Policy & Management, Erasmus University Rotterdam, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands;[email protected]
,
Saskia de Groot Institute for Medical Technology Assessment, Institute of Health Policy & Management, Erasmus University Rotterdam, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands; Institute for Medical Technology Assessment, Institute of Health Policy & Management, Erasmus University Rotterdam, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands
&
Adri Steenhoek Institute for Medical Technology Assessment, Institute of Health Policy & Management, Erasmus University Rotterdam, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands; Institute for Medical Technology Assessment, Institute of Health Policy & Management, Erasmus University Rotterdam, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands
Pages 283-292 | Published online: 09 Jan 2014

References

  • Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann. Oncol.18, 581–592 (2007).
  • Albreht TM, McKee M, Alexe DM, Coleman MP, Martin-Moreno JM. Making progress against cancer in Europe in 2008. Eur. J. Cancer44, 1451–1456 (2008).
  • Meropol NJ, Schulman KA. Perspectives on the cost of cancer care. J. Clin. Oncol.25(2), 169–170 (2007).
  • Hakama M, Coleman MP, Alexe DM, Auvinen A. Cancer screening: evidence and practice in Europe 2008. Eur. J. Cancer44, 1404–1413 (2008).
  • Fass L. Imaging and cancer: a review. Mol. Oncol.2, 115–152 (2008).
  • Fojo T, Grady C. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J. Natl Cancer Inst.101(15), 1044–1048 (2009).
  • Otto SJ, Fracheboud J, Looman CWN et al. Initiation of population-based mammography screening in Dutch municipalities and effect on breast-cancer mortality: a systematic review. Lancet361, 1411–1417 (2003).
  • Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over expresses HER2. N. Engl. J. Med.344(11), 783–792 (2001).
  • Wong Y. Financial consequences of improved treatments for colorectal cancer. Semin. Colon Rectal Surg.19(4), 247–252 (2008).
  • Karim-Kos HE, Janssen-Heijnen MLG, van Iersel CA, van der Meer RM, de Vries E, Coebergh JWW. Longkanker bij Nederlandse vrouwen: het einde in zicht. Nederlands Tijdschrift voor Geneeskunde152, 1473–1477 (2008).
  • Wheatley-Price P, Blackhall F, Thatcher N. The influence of sex in non-small cell lung cancer. Onkologie32, 547–548 (2009).
  • Bosanquet N, Sikora K. The economics of cancer care in the UK. Lancet Oncol.5, 568–574 (2004).
  • Ramsey S. What do we want from our investment in cancer research? A departure from the focus on how much money Americans spend to defeat cancer. Health AffairsW5(R), 101–104 (2005).
  • Civan A, Köksal B. The effect of newer drugs on health spending: do they really increase the costs? Health Econ.19(5), 581–595 (2009).
  • Heijink R, Noethen M, Renaud T, Koopmanschap MA, Polder JJ. Cost of illness: an international comparison Australia, Canada, France, Germany and The Netherlands. Health Policy88, 49–61 (2008).
  • Polder JJ, Meerding WJ, Koopmanschap MA, Bonneux L, van der Maas PJ. Kosten van Ziekten in Nederland 1994. Instituut Maatschappelijke gezondheidszorg, Rotterdam, The Netherlands (1997).
  • Polder JJ, Takken J, Meerding WJ, Kommer GJ, Stokx LJ. Kosten van Ziekten in Nederland, de Zorgeuro Ontrafeld (Report no. 270751005). Rijksinstituut voor Volksgezondheid en Milieu, Bilthoven, The Netherlands 5, R (2002).
  • Stichting Farmaceutische Kengetallen. Monitor dure geneesmiddelen 2008, kosten van dure- en weesgeneesmiddelen in het ziekenhuis. (2010) (In press).
  • Uyl-de Groot CA, McDonnell J, Groen HJM, Radice D, Velde GT. Cost-effectiveness of new drugs in patients with Phase IIIB–IV non-small cell lung cancer: results of a Markov chain model. Eur. J. Hosp. Pharmacy Sci.11(2), 37–41 (2005).
  • Uyl-de Groot CA, Stupp R, van der Bent M. Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme. Expert Rev. Pharmacoeconomics Outcomes Res.9(3), 235–241 (2009).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.